Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
8.07
+0.21 (2.67%)
At close: Aug 28, 2025, 4:00 PM
8.10
+0.03 (0.36%)
After-hours: Aug 28, 2025, 7:56 PM EDT
Kura Oncology Revenue
Kura Oncology had revenue of $15.29M in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $83.28M. In the year 2024, Kura Oncology had annual revenue of $53.88M.
Revenue (ttm)
$83.28M
Revenue Growth
n/a
P/S Ratio
8.46
Revenue / Employee
$433,745
Employees
192
Market Cap
700.45M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 53.88M | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
KURA News
- 15 hours ago - Kura Oncology to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 19 days ago - Kura Oncology, Inc. (KURA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Kura Oncology Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 24 days ago - Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Kura Oncology to Report Second Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes Well - Seeking Alpha
- 2 months ago - Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress - GlobeNewsWire
- 3 months ago - Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting - GlobeNewsWire